Search clinical trials for: [11C]MK-6884

Total 3898 results

Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Carcinoma, Renal Cell

United States, Australia, Canada, Chile, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)

Moderate Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Neoplasms | Head and Neck Neoplasms | Colorectal Neoplasms

Australia, Hong Kong
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

Renal Impairment

United States
Merck Sharp & Dohme LLC

Terminated

A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)

Pulmonary Hypertension | Left Heart Disease
Chinese University of Hong Kong

Completed

MK-2206 in Recurrent Nasopharyngeal Carcinoma (MC1079)

Recurrent Nasopharyngeal Carcinoma

Hong Kong
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital; University... and other collaborators

Withdrawn

MK-2206 for Recurrent Malignant Glioma

Malignant Glioma

United States
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)

Renal Insufficiency
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Tammie L. S. Benzinger, MD, PhD

Recruiting

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND) (HASD_PIB_IND)

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom, South Africa
AstraZeneca

Recruiting

A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers

Healthy Volunteers

Sweden
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Carcinoma, Renal Cell

Spain, United States, Australia, Canada, Chile, Colombia, France, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Poland, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (MOONBEAM)

Pulmonary Arterial Hypertension

Germany, United States, Poland, Spain, Colombia, France, Turkey, Israel, Australia, United Kingdom, Netherlands, South Africa
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Kidney Failure, Chronic | Renal Dialysis

United States
Merck Sharp & Dohme LLC

Completed

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Dermatitis, Atopic

United States, Belgium, Bulgaria, Canada, Romania, Spain
Merck Sharp & Dohme LLC

Completed

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Kidney Failure, Chronic | End-Stage Renal Disease | End-Stage Kidney Disease

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

Atopic Dermatitis
Merck Sharp & Dohme LLC

Terminated

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

Pharmacokinetics
Merck Sharp & Dohme LLC

Completed

Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)

Hepatic Insufficiency
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)

Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)

Alzheimer's Disease
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

Treatment Study for Cognitive Deficits in Schizophrenia (TURNS)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

Hepatitis C
Université de Sherbrooke
McMaster University; University of Ottawa

Completed

Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7) (GB7)

Type2 Diabetes

Canada
University of Pennsylvania

Recruiting

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

Tauopathies

United States
AstraZeneca

Recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Crohn's Disease

Sweden
Davidzon, Guido, M.D.
Stanford University

Suspended

Does rTMS Induce Synaptic Plasticity?

Major Depressive Disorder

United States
University of Alabama at Birmingham

Withdrawn

Cardiac Perfusion and Metabolism With [11C] Acetate PET/CT is Associated With Hematopoietic System Activation in Acute Decompensated Heart Failure: An Imaging Sub-study

Acute Decompensated Heart Failure

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer

Prostate Cancer Patients

United States
Orion Corporation, Orion Pharma

Completed

Suitability of 11C-ORM-13070 as a PET Tracer

Healthy

Finland
AstraZeneca

Not yet recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.

Crohn Disease

Sweden
GlaxoSmithKline

Completed

An Imaging Study to Investigate the Distribution of GW842166X in the Brain.

Pain, Inflammatory

Sweden
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Respiratory Syncytial Virus | Respiratory Tract Infection

United States, Chile, Colombia, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Chronic Cough

United States, Argentina, Colombia, Germany, Guatemala, Israel, Korea, Republic of, Peru, Russian Federation, Spain, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

Chronic Cough

Colombia, Guatemala, Korea, Republic of, Peru, Ukraine, United Kingdom, United States, Canada, Germany, Poland, Russian Federation, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Obstructive Sleep Apnea (OSA)

United States, Belgium
Merck Sharp & Dohme LLC

Terminated

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Acute Cough

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D)
Merck Sharp & Dohme LLC

Terminated

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Solid Tumors

3

Subscribe